EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
Data supports biologic activity of APL-2 in reducing the growth rate of geographic atrophy CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 – Apellis Pharmaceuticals,
Inspiring Scotland Names Investment Expert to Chair Its Board of Directors
Third sector funder Inspiring Scotland has appointed Sinclair Dunlop of Epidarex Capital as chair of its board of trustees. He succeeds Niall Lothian, who has
Topas Therapeutics Serves as Exclusive Translational Partner for Collaborative Research Center Focused on Liver Inflammation at University Medical Center Hamburg-Eppendorf
Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million.
Dr Enno Klussmann Joins Mironid’s SAB
January 15, 2018 – Mironid is delighted to announce the appointment of Dr Enno Klussmann to our Scientific Advisory Board Dr. Klussmann is currently a
Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to
Virginia Bio Welcomes Kyp Sirinakis to its Board of Directors
RICHMOND, Va., December 19, 2017- Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected two
Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the
Epidarex Capital Portfolio Company Harpoon Medical Acquired by Edwards Lifesciences
Acquisition Marks Further Success for the Epidarex Portfolio Bethesda, Md., December 7, 2017 – Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, today